Elizabeth Garner

No ORCID on file · 9 papers in corpus · active 2013-2022

Study types

  • article 7
  • other 1
  • rct 1

Condition tags

  • endometriosis 5
  • mesh:D017699 3
  • adenomyosis 3
  • dyspareunia 3
  • dysmenorrhea 2
  • mesh:D004715 2
  • mesh:D004414 1
  • mesh:D004412 1
rct
Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials
Lancet (London, England) ·doi:10.1016/S0140-6736(22)01475-1

BACKGROUND: Uterine fibroids are common non-cancerous neoplasm that cause heavy menstrual bleeding and other signs. Linzagolix is an oral gonadotropin-releasing hormone receptor antagonist taken once per day that dose-dependently suppresses…

other 2022
Treatment of symptomatic uterine adenomyosis with linzagolix, an oral gonadotrophin-releasing hormone antagonist: a pilot study
Reproductive biomedicine online ·doi:10.1016/j.rbmo.2021.09.019

RESEARCH QUESTION: Does a once-daily regimen of linzagolix, a new oral gonadotrophin-releasing hormone (GnRH) antagonist, given at a fully suppressive dose (200 mg) for 12 weeks, followed by a partially suppressive dose (100 mg) for a furth…

article 2021
EFFICACY AND SAFETY OF LINZAGOLIX FOR THE TREATMENT OF SEVERE ADENOMYOSIS: FINAL Results FROM A PILOT STUDY
·doi:10.1016/j.fertnstert.2021.07.881
article 2021
Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New ’Hit Hard First and then Maintain’ Regimen of Administration
Journal of clinical medicine ·doi:10.3390/jcm10245794

(1) Background: The aim of the present pilot study was to study the effect of a new oral gonadotropin-releasing hormone antagonist on adenomyosis. (2) Methods: Eight premenopausal women, aged between 37 and 45 years, presenting with heavy m…

article 2020
Linzagolix for Endometriosis-Associated Pain: Lipid Changes After 52 Weeks of Treatment [25B]
·doi:10.1097/01.aog.0000663180.46470.c9

INTRODUCTION: Linzagolix is a new, investigational, non-peptide, GnRH receptor antagonist being developed to treat endometriosis-associated pain (EAP). The EDELWEISS trial was a Phase 2b, double-blind, randomized, placebo-controlled, multic…

article 2020
Quality of Life Results After 52 Weeks of Treatment With Linzagolix for Endometriosis-Associated Pain [30B]
·doi:10.1097/01.aog.0000663200.75027.38

INTRODUCTION: Linzagolix is a new investigational, non-peptide, oral GnRH receptor antagonist being developed to treat endometriosis-associated pain (EAP). The EDELWEISS trial was a Phase 2b, double-blind, randomized, placebo-controlled, mu…

article 2015
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist: Results from a Phase 2, Randomized Controlled Study
·doi:10.5301/je.5000211

Purpose Elagolix is a novel, oral GnRH antagonist that dose-dependently suppresses estradiol levels. This study evaluated safety and efficacy of elagolix vs. leuprorelin acetate (LA) and placebo in women with endometriosis-associated pain. …

article 2014
Elagolix, an Oral GnRH Antagonist, Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis: Effects on Bone Mineral Density
Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1177/1933719114549848
article 2013
Elagolix Treatment for Endometriosis-Associated Pain: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1177/1933719113497292